Current Report Filing (8-k)

NASDAQ false 0001634379 0001634379 2023-02-03 2023-02-03

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

 

FORM 8-K

 

 

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): February 3, 2023

 

 

Metacrine, Inc.

(Exact name of registrant as specified in its charter)

 

 

 

Delaware		001-39512		47-2297384
(State or other jurisdiction of incorporation)		(Commission File Number)		(IRS Employer Identification No.)
4225 Executive Square, Suite 600 San Diego, California				92037
(Address of principal executive offices)				(Zip Code)

Registrant’s telephone number, including area code: [phone]

Not Applicable

(Former name or former address, if changed since last report)

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Stock, par value $0.0001 per share		MTCR		The Nasdaq Capital Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company  ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ☒

 

 

 

---

Item 1.02

Termination of a Material Definitive Agreement.

As previously disclosed, on August 27, 2019, Metacrine, Inc. (the “Company”) entered into a Loan and Security Agreement with K2 HealthVentures LLC, as lender and administrative agent, and Ankura Trust Company, LLC, as collateral agent (as amended to date, the “Loan Agreement”), which enabled the Company to borrow up to an aggregate of $45.0 million upon the achievement of certain milestones. In October 2021, the Company borrowed $15.0 million under the Loan Agreement.

On February 3, 2023, the Company paid in full all of its outstanding obligations and other fees under the Loan Agreement, including approximately $1.7 million of related fees and expenses, and the Loan Agreement was terminated.

 

Item 2.04

Triggering Events That Accelerate or Increase a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement.

The information set forth under Item 1.02 of this Current Report on Form 8-K is incorporated by reference into this Item 2.04.

---

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

				Metacrine, Inc.
Date: February 9, 2023				By:		/s/ Michael York
						Michael York
						President and Chief Executive Officer